Tenaya Therapeutics Files Q1 2025 10-Q
Ticker: TNYA · Form: 10-Q · Filed: May 7, 2025
Sentiment: neutral
Topics: 10-Q, financing, agreements
TL;DR
Tenaya's Q1 10-Q shows active sales agreements and loan details, key for investors tracking cash flow.
AI Summary
Tenaya Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details various agreements and events, including an At-The-Market Sales Agreement active through March 31, 2025, and a Silicon Valley Bank Loan Agreement with a Lender Warrant dated August 6, 2024. The company also reported on its Two Thousand and Twenty-One Equity Incentive Plan.
Why It Matters
This filing provides insight into Tenaya Therapeutics' ongoing financial activities and agreements, which are crucial for understanding its operational status and future funding strategies.
Risk Assessment
Risk Level: medium — The filing contains details on loan agreements and equity plans, which can indicate financial leverage and potential dilution.
Key Players & Entities
- Tenaya Therapeutics, Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of reporting period
- At-The-Market Sales Agreement (agreement) — Active agreement mentioned in filing
- Silicon Valley Bank Loan Agreement (agreement) — Loan agreement with specific dates
- August 6, 2024 (date) — Date of Silicon Valley Bank Loan Agreement
- Two Thousand and Twenty-One Equity Incentive Plan (plan) — Company incentive plan
FAQ
What is the status of the At-The-Market Sales Agreement?
The At-The-Market Sales Agreement was active through March 31, 2025, as indicated by the filing.
When was the Silicon Valley Bank Loan Agreement entered into?
The Silicon Valley Bank Loan Agreement, which includes a Lender Warrant, was dated August 6, 2024.
What is the fiscal year end for Tenaya Therapeutics, Inc.?
Tenaya Therapeutics, Inc.'s fiscal year ends on December 31.
What is the SIC code for Tenaya Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Tenaya Therapeutics, Inc. is 2836, for Biological Products (No Diagnostic Substances).
What is the filing date of this 10-Q report?
This 10-Q report was filed on May 7, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 7, 2025 regarding Tenaya Therapeutics, Inc. (TNYA).